{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:15:16Z","timestamp":1790648116265,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Dutch Arthritis Foundation (Reumafonds)","award":["14-3-404"],"award-info":[{"award-number":["14-3-404"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jaut.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T08:29:25Z","timestamp":1523867365000},"page":"97-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["TBK1: A key regulator and potential treatment target for interferon positive Sj\u00f6gren's syndrome, systemic lupus erythematosus and systemic sclerosis"],"prefix":"10.1016","volume":"91","author":[{"given":"Iris L.A.","family":"Bodewes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Huijser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia G.","family":"van Helden-Meeuwsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselotte","family":"Tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil A.S.H.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Martin","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.A.","family":"van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan A.","family":"Versnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2018.02.001_bib1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sj\u00f6gren's syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.02.001_bib2","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.02.001_bib3","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.02.001_bib4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2018.02.001_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2018.02.001_bib6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/annrheumdis-2016-209589","article-title":"Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sj\u00f6gren's syndrome","volume":"76","author":"Maria","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.02.001_bib7","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.39795","article-title":"Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease","volume":"68","author":"Mavragani","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2018.02.001_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/art.40122","article-title":"Brief report: blockade of TANK-binding kinase 1\/IKK\u025b inhibits mutant stimulator of interferon genes (STING)\u2013Mediated inflammatory responses in human peripheral blood mononuclear cells","volume":"69","author":"Fr\u00e9mond","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2018.02.001_bib9","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1084\/jem.20161596","article-title":"Type I interferon\u2013mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview","volume":"213","author":"Rodero","year":"2016","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.jaut.2018.02.001_bib10","first-page":"491","article-title":"IKK[epsi] and TBK1 are essential components of the IRF3 signaling pathway","volume":"4","author":"Fitzgerald","year":"2003"},{"key":"10.1016\/j.jaut.2018.02.001_bib11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1126\/science.1081315","article-title":"Triggering the interferon antiviral response through an IKK-related pathway","volume":"300","author":"Sharma","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jaut.2018.02.001_bib12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.1136567","article-title":"Multiple functions of the IKK-related kinase IKK\u03b5 in interferon-mediated antiviral immunity","volume":"315","author":"tenOever","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jaut.2018.02.001_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol. Hoboken N. J."},{"key":"10.1016\/j.jaut.2018.02.001_bib14","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.02.001_bib15","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.02.001_bib16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.02.001_bib17","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-\u03b1\u2013induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.02.001_bib18","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.02.001_bib19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1517\/13543776.2015.1081168","article-title":"TBK1 inhibitors: a review of patent literature (2011 \u2013 2014)","volume":"25","author":"Yu","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jaut.2018.02.001_bib20","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.4049\/jimmunol.1500162","article-title":"Cutting edge: inhibiting TBK1 by compound II ameliorates autoimmune disease in mice","volume":"195","author":"Hasan","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2018.02.001_bib21","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.33494","article-title":"Enhanced interferon regulatory factor 3 binding to the interleukin-23p19 promoter correlates with enhanced interleukin-23 expression in systemic lupus erythematosus","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.02.001_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13075-017-1501-z","article-title":"Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?","volume":"20","author":"Wahadat","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2018.02.001_bib23","first-page":"61","article-title":"Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes","volume":"14","author":"Hasan","year":"2013"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117308041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117308041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:18:06Z","timestamp":1760257086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841117308041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":23,"alternative-id":["S0896841117308041"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2018.02.001","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TBK1: A key regulator and potential treatment target for interferon positive Sj\u00f6gren's syndrome, systemic lupus erythematosus and systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}